Key facts
- This page summarizes Seah H. Lim's Form 4 filing for Emmaus Life Sciences, Inc. (EMMA).
- 7 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Dec 2023, 19:44.
Seah H. Lim - 09 Oct 2022 Form 4 Insider Report for Emmaus Life Sciences, Inc. (EMMA)
- Reporting relationship
- Director
- Issuer ticker
- EMMA
- Reported as of
- 09 Oct 2022
- Net transaction value
- +$1,320,010
- SEC form
- 4
- Accepted by SEC
- 19 Dec 2023, 19:44:30 UTC
- Prior SEC filing
- 06 Oct 2022
- Next SEC filing
- 17 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- Seah H. Lim
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Seah H. Lim filed Form 4 for Emmaus Life Sciences, Inc. (EMMA) on 19 Dec 2023.
Change
- Previous filing in this sequence was filed on 06 Oct 2022.
- Current net transaction value: +$1,320,010.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EMMA
transaction
Common stock, $0.001 par value
Purchase
- Transaction value
- $2,794
- Shares
- +25,400
- Change %
- +66%
- Price
- $0.1100
- Shares after
- 63,900
- Date
- 09 Oct 2022
- Ownership
- Direct
EMMA
transaction
Common stock, $0.001 par value
Purchase
- Transaction value
- $24,867
- Shares
- +92,100
- Change %
- +144%
- Price
- $0.2700
- Shares after
- 156,000
- Date
- 25 Aug 2023
- Ownership
- Direct
- Footnotes
- F1
EMMA
transaction
Common stock, $0.001 par value
Purchase
- Transaction value
- $3,000
- Shares
- +20,000
- Change %
- +13%
- Price
- $0.1500
- Shares after
- 176,000
- Date
- 30 Aug 2023
- Ownership
- Direct
EMMA
transaction
Common stock, $0.001 par value
Purchase
- Transaction value
- $255
- Shares
- +1,700
- Change %
- +0.97%
- Price
- $0.1500
- Shares after
- 177,700
- Date
- 05 Sep 2023
- Ownership
- Direct
EMMA
transaction
Common stock, $0.001 par value
Sale
- Transaction value
- $660
- Shares
- -6,000
- Change %
- -3.4%
- Price
- $0.1100
- Shares after
- 171,700
- Date
- 15 Dec 2023
- Ownership
- Direct
EMMA
transaction
Common stock, $0.001 par value
Other
- Transaction value
- $1,289,754
- Shares
- +4,447,426
- Change %
- +2590%
- Price
- $0.2900
- Shares after
- 4,619,126
- Date
- 15 Dec 2023
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EMMA
transaction
Derivative
Promissory Note due 9/16/2025
Other
- Transaction value
- Shares
- -240,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 15 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 240,000
- Exercise price
- $0.2900
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.20 to $0.27, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).
Footnote F2
The shares shown were issued in exchange for principal and accrued interest under the promissory note of the Issuer held by the reporting person referred to in footnote (2), below, which promissory note was surrendered by the reporting person for cancellation.
Footnote F3
Promissory Note due 9/16/2025 surrendered for cancellation in exchange for shares of common stock referred to in footnote (1) above.
Footnote F4
Represent shares previously issuable upon maturity of the Promissory Note due 9/16/2025.